For example, Tampa General Hospital clinicians use an AI-driven model to identify patients in the neurology intensive care unit (ICU) who are ready for transfer to a lower-level unit
Independent reporting on semaglutide, tirzepatide, compounding, side effects, and everything in between
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
Furthermore, it is important to note that research findings from the FDA Adverse Event Reporting System may have certain limitations and may not be easily generalizable to the entire population
This dual action helps maintain healthier glucose levelsa vital benefit for our patients with type 2 diabetes
If you are taking any medications, its important to discuss potential interactions with your healthcare provider
